1. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(10010):2287–2323.
2. Korea Centers for Disease Control and Prevention. Chronic disease status and issues. Cheongju: Korea Centers for Disease Control and Prevention;2015.
3. Majno G, Joris I. Cells, tissues, and disease: principles of general pathology. 2nd edition. New York (NY): Oxford University Press;2004.
4. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428–435.
Article
5. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003; 3(4):276–285.
Article
6. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993; 91(4):1351–1357.
Article
7. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Centers for Disease Control and Prevention. American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499–511.
8. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999; 106(5):506–512.
9. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther. 2010; 4:383–413.
10. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002; 106(23):2908–2912.
Article
11. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17(10):2167–2176.
Article
12. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353(9165):1649–1652.
Article
13. Muhammad IF, Borné Y, Hedblad B, Nilsson PM, Persson M, Engström G. Acute-phase proteins and incidence of diabetes: a population-based cohort study. Acta Diabetol. 2016; 53(6):981–989.
Article
14. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004; 93(10):1238–1242.
Article
15. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14):973–979.
16. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr. 2006; 84(6):1489–1497.
Article
17. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003; 107(3):443–447.
Article
18. Soltani S, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) on serum inflammatory markers: a systematic review and meta-analysis of randomized trials. Clin Nutr. 2017; Forthcoming.
Article
19. Khayyatzadeh SS, Kazemi-Bajestani SM, Bagherniya M, Mehramiz M, Tayefi M, Ebrahimi M, Ferns GA, Safarian M, Ghayour-Mobarhan M. Serum high C reactive protein concentrations are related to the intake of dietary macronutrients and fiber: findings from a large representative Persian population sample. Clin Biochem. 2017; 50(13-14):750–755.
Article
20. Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: findings from National Health and Nutrition Examination Survey Data. J Nutr. 2004; 134(5):1181–1185.
Article
21. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol. 2003; 92(11):1335–1339.
Article
22. Lee Y, Kang D, Lee SA. Effect of dietary patterns on serum C-reactive protein level. Nutr Metab Cardiovasc Dis. 2014; 24(9):1004–1011.
Article
23. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157–163.
24. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek EJ 3rd, Li W, Pagoto SL, Hafner AR, Ockene IS. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 2006; 83(4):760–766.
Article
25. Ma Y, Hébert JR, Li W, Bertone-Johnson ER, Olendzki B, Pagoto SL, Tinker L, Rosal MC, Ockene IS, Ockene JK, Griffith JA, Liu S. Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. Nutrition. 2008; 24(10):941–949.
Article
26. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κ B-dependent signaling. Eur J Cell Biol. 2012; 91(6-7):496–505.
27. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem. 1998; 44(6 Pt 1):1358–1361.
Article
28. Ledue TB, Rifai N. High sensitivity immunoassays for C-reactive protein: promises and pitfalls. Clin Chem Lab Med. 2001; 39(11):1171–1176.
Article
29. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2002; 144(2):233–238.
Article
30. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009; 54(25):2388–2395.
31. Hur M, Lee YK, Kang HJ, Lee KM. Distribution of high-sensitivity C-reactive protein in Korean healthy individuals. J Clin Pathol Qual Control. 2001; 23(2):259–263.
32. Lear SA, Chen MM, Birmingham CL, Frohlich JJ. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism. 2003; 52(12):1542–1546.
Article
33. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004; 24(8):1509–1515.
Article
34. Rallidis LS, Kolomvotsou A, Lekakis J, Farajian P, Vamvakou G, Dagres N, Zolindaki M, Efstathiou S, Anastasiou-Nana M, Zampelas A. Short-term effects of Mediterranean-type diet intervention on soluble cellular adhesion molecules in subjects with abdominal obesity. Clin Nutr ESPEN. 2017; 17:38–43.
Article
35. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999; 69(1):30–42.
Article
36. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011; 3(10):858–876.
Article
37. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002; 252(4):283–294.
Article
38. Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, Bergeron J, Després JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001; 21(6):961–967.
39. Navarro SL, Kantor ED, Song X, Milne GL, Lampe JW, Kratz M, White E. Factors associated with multiple biomarkers of systemic inflammation. Cancer Epidemiol Biomarkers Prev. 2016; 25(3):521–531.
Article
40. Jafari Salim S, Alizadeh S, Djalali M, Nematipour E, Hassan Javanbakht M. Effect of omega-3 polyunsaturated fatty acids supplementation on body composition and circulating levels of follistatin-like 1 in males with coronary artery disease: a randomized double-blind clinical trial. Am J Mens Health. 2017; 11(6):1758–1764.
Article
41. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001; 36(9):1007–1024.
Article
42. Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003; 24(14):1365–1372.
43. Donges CE, Duffield R, Drinkwater EJ. Effects of resistance or aerobic exercise training on interleukin-6, C-reactive protein, and body composition. Med Sci Sports Exerc. 2010; 42(2):304–313.
Article
44. Richardson MR, Churilla JR. Sleep duration and C-reactive protein in US adults. South Med J. 2017; 110(4):314–317.
Article
45. Ironson G, Banerjee N, Fitch C, Krause N. Positive emotional well-being, health behaviors, and inflammation measured by C-reactive protein. Soc Sci Med. 2017; Forthcoming.
Article